Has Drew Barrymore confirmed she is taking HRT?

Barrymore has confirmed she discussed HRT with her doctor and considered it during her perimenopause journey, based on her public statements on her talk show. She has not confirmed a specific regimen, dose, or whether she is currently taking any hormone therapy. Any claim beyond that is speculated.

What are the risks of stopping HRT abruptly?

Abrupt discontinuation can trigger a rebound of vasomotor symptoms in approximately half of women, with some experiencing symptoms more severe than before they started HRT. Bone loss also resumes at a faster rate immediately after stopping. Most clinicians prefer a gradual taper over four to sixteen weeks to reduce these effects.

Is there a time limit on how long you can take HRT?

Current guidance from the Menopause Society states there is no arbitrary time limit for appropriate candidates. The decision to continue or stop should be reviewed annually with a clinician, weighing individual cardiovascular, breast cancer, and bone health risks against ongoing symptom burden.

What is the difference between bioidentical and conventional HRT?

Bioidentical hormones have a molecular structure identical to endogenous human hormones, such as 17-beta estradiol and micronized progesterone. Many FDA-approved HRT products are bioidentical by this definition. Compounded bioidentical preparations are not FDA-regulated for potency or purity and have a different evidence and regulatory standing than approved products.

What is the perimenopause 'window of opportunity' for HRT?

Research suggests that initiating HRT close to the onset of menopause, generally within ten years of the final menstrual period or before age 60, is associated with more favorable cardiovascular outcomes than initiating it in later post-menopause. This is sometimes called the timing hypothesis or the critical window hypothesis.

Drew Barrymore, Maintenance, and What Happens If You Stop

By HealthRX Medical Team

Published Jul 14, 2025Updated Jul 14, 2025Last reviewed Jul 14, 2025

At a glance

What Drew Barrymore Has Actually Said

Drew Barrymore, born February 22, 1975, has spoken openly on The Drew Barrymore Show and in associated press about experiencing perimenopause, describing symptoms including weight changes, mood shifts, and the general confusion that often accompanies that phase of reproductive life. In a segment that drew wide coverage from outlets including People magazine, she discussed consulting her doctor about HRT and framed the conversation as something women should feel comfortable having in public.

To be precise about what is and is not confirmed: Barrymore has confirmed she discussed HRT with her physician and considered it. She has not publicly confirmed which hormone, which formulation, which route of administration, or whether she ultimately started a protocol. Any characterization beyond "HRT consideration" is speculated. The HealthRX Medical Team will not state speculation as fact here.

What she has done, regardless of her personal treatment decision, is put the phrase "hormone replacement therapy" in front of a daytime television audience in a way that reduces stigma. That is the opening the clinical conversation needs.

Why Perimenopause Is the Critical Window

Perimenopause, the transition phase that can begin as early as the mid-30s and typically spans two to twelve years before the final menstrual period, is characterized by erratic estradiol secretion, rising FSH, and fluctuating progesterone. The North American Menopause Society recognizes vasomotor symptoms, sleep disturbance, mood disruption, and genitourinary changes as the core clinical burden of this period.

When women first consider HRT, the timing relative to menopause matters enormously. The "timing hypothesis," sometimes called the critical window or window of opportunity, holds that initiating estrogen therapy early in menopause, before significant arterial aging has occurred, confers cardiovascular benefit, while initiation in later post-menopause may not. A 2022 analysis in JAMA Internal Medicine confirmed that women who began HRT within six years of menopause onset had meaningfully different cardiovascular risk profiles than those who initiated a decade or more later.

For women in Barrymore's approximate age cohort at the time of her public disclosure, perimenopause-stage initiation, if clinically appropriate, falls squarely within that favorable window.

What HRT Actually Does: Mechanism and Formulations

Estrogen replacement, the pharmacological core of HRT, works by binding estrogen receptors (ER-alpha and ER-beta) distributed across the hypothalamus, vasculature, bone, brain, and genitourinary tract. Restoring circulating estradiol suppresses thermoregulatory instability, which is the direct cause of hot flashes, while also maintaining bone mineral density and supporting vaginal epithelial integrity.

The FDA-approved formulations span oral estrogens (conjugated equine estrogen, micronized 17-beta estradiol), transdermal patches, gels, sprays, and vaginal preparations. Transdermal estradiol avoids first-pass hepatic metabolism and is associated with lower risk of venous thromboembolism compared with oral formulations, a distinction that matters clinically when weighing options for individual patients.

In women with an intact uterus, a progestogen must accompany systemic estrogen to prevent endometrial hyperplasia. Micronized progesterone (bioidentical) appears to carry a more favorable breast cancer and cardiovascular signal than synthetic progestins based on observational data, though the randomized evidence base remains smaller. The Lancet reanalysis of collaborative data published in 2019 found that combined estrogen-progestogen regimens carried higher breast cancer risk than estrogen-only therapy, with the excess risk varying by progestogen type.

The Maintenance Question: How Long Is Long Enough?

This is the page's central clinical argument: starting HRT is a decision; staying on it or stopping it are equally active decisions that deserve the same rigorous clinical thinking.

No universal stopping point exists. Older guidance, partly derived from the original Women's Health Initiative framing, implied HRT should be limited to two to five years. Current thinking from the Menopause Society and the Endocrine Society has shifted substantially. For women with significant vasomotor symptoms, documented osteopenia, or genitourinary syndrome, continuation beyond five years may be clinically justified when the individual's cardiovascular, breast cancer, and thromboembolic risk profile supports it.

A 2023 position statement from the Menopause Society states explicitly that there is no arbitrary time limit on HRT for appropriate candidates and that the question should be revisited annually with the treating clinician.

For women who are candidates for long-term maintenance, the monitoring framework generally includes:

Annual blood pressure assessment and lipid review
Periodic endometrial surveillance if breakthrough bleeding occurs on combined therapy
Breast cancer screening per standard age-based guidelines, with shared decision-making about the modest incremental risk of combined therapy
Bone mineral density assessment (DEXA) every one to two years if osteoporosis prevention is a stated treatment goal

What Happens When You Stop: The Biology of Discontinuation

This is where the clinical picture gets underappreciated in popular media. When exogenous estrogen is withdrawn, the body does not simply return to baseline. Symptoms frequently rebound, sometimes more severely than before initiation, because the hypothalamic thermostat has become recalibrated to the higher estrogen environment.

A study published in JAMA Internal Medicine found that abrupt HRT discontinuation led to a return of moderate-to-severe vasomotor symptoms in approximately 50 percent of women, regardless of how long they had been on therapy. The symptoms were not always temporary. For a subset, significant symptoms persisted for more than a year after stopping.

Bone loss resumes at discontinuation. The skeletal protection of estrogen is not banked. Data from the WHI follow-up showed that the relative reduction in fracture risk seen during active treatment largely disappeared within a few years of stopping, with bone density declining at an accelerated rate immediately post-discontinuation.

Genitourinary symptoms, sometimes called genitourinary syndrome of menopause (GSM), tend to worsen after stopping systemic estrogen because they depend on ongoing estrogen receptor stimulation. Low-dose vaginal estrogen, which has minimal systemic absorption, can often be continued even when systemic HRT is stopped, giving clinicians a tool to address GSM without re-exposing patients to the risks of systemic therapy.

Tapering vs. Abrupt Discontinuation

Many clinicians recommend tapering rather than abrupt discontinuation, though the evidence base for specific tapering protocols is limited. The rationale is physiological: a gradual reduction allows the hypothalamic-pituitary axis to readjust to lower estrogen levels less abruptly, potentially reducing rebound symptom severity.

Common tapering approaches include reducing the estrogen dose by one step every four to eight weeks, or switching from daily use to alternate-day use before stopping. No randomized trial has compared tapering regimens head to head on symptom outcomes, a gap the NIH MsFLASH network has been studying in related vasomotor symptom research.

The HealthRX Medical Team Take

Drew Barrymore's willingness to say "I am talking to my doctor about hormones" on a daytime talk show does real-world clinical good. Women delay menopause treatment on average for years, partly due to stigma and partly due to lingering fear from the original 2002 WHI press coverage, which was misread by clinicians and patients alike as a blanket condemnation of HRT when the actual findings were far more nuanced.

Her specific treatment decisions are her own and have not been publicly disclosed in enough detail to analyze. What the HealthRX Medical Team can say clearly is this: the conversation she is modeling, bring your symptoms to your doctor, discuss the options, weigh the data, check in annually, is precisely the conversation the medical literature supports.

If Barrymore or any woman in her position is currently on HRT, the maintenance calculus is not "how quickly can I stop" but "what is my individual risk profile and what are my ongoing symptoms." If she has stopped or is considering stopping, the discontinuation physiology matters: bone loss resumes, vasomotor symptoms may return, and a managed taper is generally preferable to abrupt withdrawal. These are not abstract risks. They are documented, quantifiable, and manageable with good clinical partnership.

The public-health value of a celebrity being honest about perimenopause is not that her choices become a template. It is that her honesty gives other women permission to have the same conversation with their own physicians.

Frequently asked questions

›

References

Menopause Society Position Statement on Hormone Therapy (2022): https://www.menopause.org
Collaborative Group on Hormonal Factors in Breast Cancer. "Type and timing of menopausal hormone therapy and breast cancer risk." The Lancet, 2019. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31709-X/fulltext
Manson JE, et al. "Menopausal hormone therapy and long-term all-cause and cause-specific mortality." JAMA, 2017. https://jamanetwork.com
Rossouw JE, et al. "Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause." JAMA, 2007. https://jamanetwork.com
Anderson GL, et al. "Effects of stopping postmenopausal hormone therapy." JAMA Internal Medicine, 2004. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2091630
Cauley JA, et al. "Effects of estrogen plus progestin on risk of fracture and bone mineral density." WHI Follow-up. JAMA, 2003. https://pubmed.ncbi.nlm.nih.gov/21521849/
Endocrine Society Clinical Practice Guideline: Menopause. https://www.endocrine.org
FDA: Approved HRT products database. https://www.accessdata.fda.gov/scripts/cder/daf/
Drew Barrymore perimenopause segment, People magazine coverage: https://people.com